206 related articles for article (PubMed ID: 20598596)
1. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
[TBL] [Abstract][Full Text] [Related]
2. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
Queiroga FL; Pires I; Lobo L; Lopes CS
Res Vet Sci; 2010 Jun; 88(3):441-5. PubMed ID: 19939424
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
[TBL] [Abstract][Full Text] [Related]
5. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
Ferreira E; Bertagnolli AC; Cavalcanti MF; Schmitt FC; Cassali GD
Vet Comp Oncol; 2009 Dec; 7(4):230-5. PubMed ID: 19891693
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
8. Human and canine mammary tumors: a role for urokinase plasminogen activator?
McGill LD
Vet J; 2011 Jul; 189(1):1-2. PubMed ID: 21382730
[No Abstract] [Full Text] [Related]
9. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Reilly D; Andreasen PA; Duffy MJ
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of regional lymph node status in canine mammary carcinomas.
Szczubiał M; Łopuszynski W
Vet Comp Oncol; 2011 Dec; 9(4):296-303. PubMed ID: 22077411
[TBL] [Abstract][Full Text] [Related]
13. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
14. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
15. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
18. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study.
De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Dos Santos MS; Rutteman GR; Gärtner Mde F
Anticancer Res; 2006; 26(3A):1821-6. PubMed ID: 16827113
[TBL] [Abstract][Full Text] [Related]
19. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
20. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
